Literature DB >> 25433820

A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer.

Fausto Petrelli1, Andrea Coinu, Veronica Lonati, Sandro Barni.   

Abstract

BACKGROUND: Current guidelines support the use of adjuvant chemotherapy (CT) following neoadjuvant chemoradiotherapy (CTRT) and surgery to treat rectal cancer, although clinical trials have provided little evidence that it is effective. We performed a systematic review of published studies to assess whether adjuvant CT improves outcome after neoadjuvant therapy and radical surgery in cases of rectal cancer.
MATERIALS AND METHODS: We conducted an electronic database search for randomized and nonrandomized studies in PubMed, EMBASE, Web of Science, Scopus and the Cochrane Register of Controlled Trials. We then carried out a meta-analysis by using the fixed- or random-effects models. The primary endpoint was 5-year overall survival (OS) reported as odds ratios (ORs) and 95% confidence intervals (CIs).
RESULTS: Two randomized controlled trials (RCTs), one pooled analysis of five RCTs and 10 retrospective studies that included a total of 5,457 patients matched our selection criteria. Meta-analysis showed that for rectal cancer patients treated with surgery and neoadjuvant CTRT, adjuvant CT improves 5-year OS (OR, 0.64; 95% CI, 0.46-0.88; p = 0.006) and 5-year disease-free survival (DFS) (OR, 0.71; 95% CI, 0.6-0.83; p < 0.0001). The 5-year OS benefit was significantly larger in downstaged patients and in retrospective series. A better DFS was instead noted in all studies due to a reduced risk of local relapse.
CONCLUSIONS: Amongst rectal cancer patients treated with neoadjuvant therapy and surgery, adjuvant CT seems to improve the 5-year DFS and OS rates and may be discussed with patients. However, the benefit derives mainly from retrospective evidence.

Entities:  

Mesh:

Year:  2014        PMID: 25433820     DOI: 10.1007/s00384-014-2082-9

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  29 in total

1.  Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials.

Authors:  Vincenzo Valentini; Ruud G P M van Stiphout; Guido Lammering; Maria Antonietta Gambacorta; Maria Cristina Barba; Marek Bebenek; Franck Bonnetain; Jean-Francois Bosset; Krzysztof Bujko; Luca Cionini; Jean-Pierre Gerard; Claus Rödel; Aldo Sainato; Rolf Sauer; Bruce D Minsky; Laurence Collette; Philippe Lambin
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

2.  Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

Authors:  Hajime Uno; Brian Claggett; Lu Tian; Eisuke Inoue; Paul Gallo; Toshio Miyata; Deborah Schrag; Masahiro Takeuchi; Yoshiaki Uyama; Lihui Zhao; Hicham Skali; Scott Solomon; Susanna Jacobus; Michael Hughes; Milton Packer; Lee-Jen Wei
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

3.  Oncologic outcomes of primary and post-irradiated early stage rectal cancer: a retrospective cohort study.

Authors:  Chang-Zheng Du; Yong-Chun Chen; Yong Cai; Wei-Cheng Xue; Jin Gu
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

4.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

Review 5.  Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer.

Authors:  Laura De Caluwé; Yves Van Nieuwenhove; Wim P Ceelen
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

6.  Outcomes of clinical T4M0 extra-peritoneal rectal cancer treated with preoperative radiochemotherapy and surgery: a prospective evaluation of a single institutional experience.

Authors:  Vincenzo Valentini; Claudio Coco; Gianluca Rizzo; Alberto Manno; Antonio Crucitti; Claudio Mattana; Carlo Ratto; Alessandro Verbo; Fabio M Vecchio; Brunella Barbaro; Maria A Gambacorta; Caterina Montoro; Maria C Barba; Luigi Sofo; Valerio Papa; Roberta Menghi; Domenico M D'Ugo; Giovanbattista Doglietto
Journal:  Surgery       Date:  2009-03-21       Impact factor: 3.982

7.  Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies.

Authors:  Fausto Petrelli; Giovanni Sgroi; Enrico Sarti; Sandro Barni
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

8.  Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.

Authors:  Laurence Collette; Jean-Francois Bosset; Marcel den Dulk; France Nguyen; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Marianne Piérart; Gilles Calais
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

9.  Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.

Authors:  Yu Jo Chua; Yolanda Barbachano; David Cunningham; Jacqui R Oates; Gina Brown; Andrew Wotherspoon; Diana Tait; Alison Massey; Niall C Tebbutt; Ian Chau
Journal:  Lancet Oncol       Date:  2010-01-25       Impact factor: 41.316

10.  Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0.

Authors:  Kai-yun You; Rong Huang; Pei-rong Ding; Bo Qiu; Guan-qun Zhou; Hui Chang; Wei-wei Xiao; Zhi-fan Zeng; Zhi-zhong Pan; Yuan-hong Gao
Journal:  Int J Colorectal Dis       Date:  2014-01-29       Impact factor: 2.571

View more
  23 in total

1.  Association between TCF7L2 polymorphisms and breast cancer susceptibility: a meta-analysis.

Authors:  Feng Wang; Lixin Jiang; Jianlin Li; Xiao Yu; Mingchuan Li; Guochang Wu; Zhenyu Yu; Kai Zhou; Haidi Chu; Huiyuan Zhai
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 2.  Adjuvant chemotherapy for rectal cancer: Is it needed?

Authors:  Kristijonas Milinis; Michael Thornton; Amir Montazeri; Paul S Rooney
Journal:  World J Clin Oncol       Date:  2015-12-10

Review 3.  Recent advances in multidisciplinary approach for rectal cancer.

Authors:  Eiji Oki; Koji Ando; Yuta Kasagi; Yoko Zaitsu; Masahiko Sugiyama; Yuichiro Nakashima; Hideto Sonoda; Kippei Ohgaki; Hiroshi Saeki; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2015-06-23       Impact factor: 3.402

4.  Interplay between long noncoding RNA ZEB1-AS1 and miR-101/ZEB1 axis regulates proliferation and migration of colorectal cancer cells.

Authors:  Wan-Cheng Xiong; Na Han; Nan Wu; Ke-Lei Zhao; Chen Han; Hui-Xin Wang; Guan-Fang Ping; Peng-Fei Zheng; Hailong Feng; Lei Qin; Peng He
Journal:  Am J Transl Res       Date:  2018-02-15       Impact factor: 4.060

5.  Adjuvant Chemotherapy Seemed Not to Have Survival Benefit in Rectal Cancer Patients with ypTis-2N0 After Preoperative Radiotherapy and Surgery from a Population-Based Propensity Score Analysis.

Authors:  Xiang Hu; Ya-Qi Li; Qing-Guo Li; Yan-Lei Ma; Jun-Jie Peng; San-Jun Cai
Journal:  Oncologist       Date:  2018-04-19

6.  Adjuvant treatment for resected rectal cancer: impact of standard and intensified postoperative chemotherapy on disease-free survival in patients undergoing preoperative chemoradiation-a propensity score-matched analysis of an observational database.

Authors:  Benjamin Garlipp; Henry Ptok; Frank Benedix; Ronny Otto; Felix Popp; Karsten Ridwelski; Ingo Gastinger; Christoph Benckert; Hans Lippert; Christiane Bruns
Journal:  Langenbecks Arch Surg       Date:  2016-11-09       Impact factor: 3.445

7.  Prognostic Significance of Neoadjuvant Rectal Score and Indication for Postoperative Adjuvant Therapy in Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy.

Authors:  Kiyoshi Maeda; Masatsune Shibutani; Akiko Tachimori; Takafumi Nishii; Naoki Aomatsu; Tatsunari Fukuoka; Hisashi Nagahara; Hiroshi Otani; Toru Inoue; Masaichi Ohira
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

8.  Adjuvant versus neoadjuvant chemoradiotherapy in distal rectal cancer: Comparison of two decades in a single center.

Authors:  Baha Zengel; Adam Uslu; Zehra Adıbelli; Halit Yetiş; Fevzi Cengiz; Ahmet Aykas; Cenk Şimşek; Göksever Akpınar; Nuket Eliyatkın; Ali Duran
Journal:  Ulus Cerrahi Derg       Date:  2015-12-01

9.  Is adjuvant chemotherapy necessary for locally advanced rectal cancer patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery? A systematic review and meta-analysis.

Authors:  Bin Ma; Yupeng Ren; Yue Chen; Bo Lian; Peng Jiang; Yongmin Li; Yan Shang; Qingkai Meng
Journal:  Int J Colorectal Dis       Date:  2018-10-27       Impact factor: 2.571

10.  Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection.

Authors:  Fahima Dossa; Sergio A Acuna; Aaron S Rickles; Mariana Berho; Steven D Wexner; Fayez A Quereshy; Nancy N Baxter; Sami A Chadi
Journal:  JAMA Oncol       Date:  2018-07-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.